Baidu
map

阿司匹林&海洛因之父:天使or魔鬼?

2014-11-17 伊文 中国科学报

霍夫曼一生中有诸多发明创造,但正是阿司匹林和海洛因,让他成为站在天使与魔鬼之间那个颇为无奈而尴尬的人。 阿司匹林和海洛因,一个如天使带来福音,一个似魔鬼引发罪恶。就连上帝恐怕也没有想到,两者皆出自同一个科学家之手。而这位科学家更不曾料到,天使与魔鬼都在百年之间风靡全世界。 德国化学家菲利克斯 霍夫曼一生中有诸多发明创造,但正是阿司匹林和海洛因,让他成为站在天使与魔鬼之间

霍夫曼一生中有诸多发明创造,但正是阿司匹林海洛因,让他成为站在天使魔鬼之间那个颇为无奈而尴尬的人。

阿司匹林和海洛因,一个如天使带来福音,一个似魔鬼引发罪恶。就连上帝恐怕也没有想到,两者皆出自同一个科学家之手。而这位科学家更不曾料到,天使与魔鬼都在百年之间风靡全世界。

德国化学家菲利克斯 霍夫曼一生中有诸多发明创造,但正是阿司匹林和海洛因,让他成为站在天使与魔鬼之间那个颇为无奈而尴尬的人。

已有百余年历史的阿司匹林与青霉素、安定并称“医药史上三大经典药物”,它为人类减少死亡、延长寿命,尤其是为降低心梗死亡率提供了简单、经济而有效的手段。然而,从阿司匹林诞生的那一刻起,围绕它的争论就从未停止过,其中便包括“真正的发明者之争”。

1897年的一天,29岁的霍夫曼接到导师通知,让他停止手头对煤焦油的研究,开始专攻“水杨酸”这种药物的改进,制造出更为稳定、副作用更小的解热镇痛药。

霍夫曼对水杨酸并不陌生,它也并非什么新发明。事实上,霍夫曼的父亲很早之前就在用水杨酸驱除关节炎带来的疼痛,但它引起的呕吐和胃部不适让人痛不欲生。原因是,尽管水杨酸能镇痛,但它有着几乎无法去除的副作用——损伤胃黏膜,甚至导致胃出血。

或许是无法忍受父亲因服药带来的巨大痛苦,霍夫曼接受了这项任务。而他所在的拜耳药厂则希望,霍夫曼能够使水杨酸从一个土方子变成更加可靠的商业化药物。

此后,霍夫曼梳理了一系列论文,终于找到了一种方法,生产出稳定而副作用较小的乙酰水杨酸作为替代物。从此,风湿病治疗的历史被改变了。

比其他产品研发人员幸运的是,霍夫曼背后有一家强大的公司。拜耳做了其他制药公司不屑于做的两件事情,一是为化学品乙酰水杨酸取了个商标名“阿司匹林”,二是为其生产技术和工艺在很多国家注册了专利权。1899年3月6日,阿司匹林的发明专利申请被通过,商品专利号为36433,这种药物开始在位于德国伍珀塔尔的埃尔伯福特工厂生产。

迄今为止,上述关于阿司匹林发明者的说法,都来自于德国化学家奥尔布赖特 施特在一篇关于工业化学的论着中对阿司匹林所作的注脚。短短的几行字,在很长一段时间内被认为是阿司匹林发明过程的解说词,霍夫曼也就成为了人们争相传颂的人物。

直到十几年前,人们开始对阿司匹林的发现者提出新的疑问。

1999年2月20日,英国《泰晤士报》为纪念阿司匹林发明百年刊登了一篇特别报道。该报道除了照搬阿司匹林的解说词外,还提及另外一位名为亨利希 德莱塞的科学家,说是经过德莱塞和霍夫曼商量后,才以“阿司匹林”(aspirin)为药名。同时,德莱塞在1899年发表的一篇题为《阿司匹林(乙酰水杨酸)的药理学》的文章被重新翻了出来,并由此认定他是阿司匹林的发现者之一。

2000年底,英国伦敦一所大学的药物部副主任沃尔特?斯奈德,又为当年在拜耳药厂工作的犹太化学家阿瑟 艾兴格林进行了辩护,指出艾兴格林与霍夫曼同在药剂室工作。艾兴格林1944年被德国纳粹抓进了集中营,他在一封信中首次提到,是他授意霍夫曼合成乙酰水杨酸。

斯奈德还提到,霍夫曼活到1946年,但他从来没有就发现阿司匹林一事发表过自己的任何看法。

霍夫曼不可能想到,在自己逝世半个世纪后会陷入一场名誉之争。然而,经他之手问世的“海洛因”,则在他生前就已切切实实成为了“魔鬼的杰作”。

1897年8月21日,霍夫曼在实验室里合成了一种叫作二乙酰吗啡的物质,止痛效力远高于能让人上瘾的吗啡。老板们喜出望外,当证实一些用于实验的鱼、海马和猫吞下这些药物依然能够活命之后,公司的家属包括孩子也开始试着服用,没毒死人,也没有人上瘾。于是,在合成后不到一年,在没有进行彻底的临床试验的情况下,公司便将它上市销售。

拜耳公司的老板们认为发明这一物质是“英雄般”的事迹,因此为其取名为“海洛因(Heroin)”,在德文中意为“英雄”。接下来,便是世界医药历史上最为荒谬的一页。

直到上世纪30年代,拜耳公司还在销售高纯度的海洛因。世界各地都对这种药效强劲、用途广泛的药品欢呼雀跃,成千上万的病人争相服用,从婴幼儿、成年人到老人都是海洛因的消费者,它以粉末、混合剂或栓剂的形式被使用。

当这种药品上市时,除了大获成功之外,看不出它有任何异常之处。医生们记录的海洛因的副作用是昏沉、晕眩和便秘,没有别的。警告海洛因有上瘾危险的医生只是少数。事实上,海洛因是否上瘾的关键在于当时盛行的服用方式,口服的海洛因经过很长时间才抵达脑部。

1910年后,情况发生了改变。饱受鸦片和吗啡滥用之苦的美国在1909年通过了《排斥吸食鸦片法案》,瘾君子开始寻找替代品。与吗啡相比,海洛因的管控更宽松,吸毒者发现,海洛因能否比吗啡的“药效”更强也只是时间问题。海洛因理所当然取代了吗啡,成为被滥用的主力军。

后来,柏林的药剂师米歇尔 德 里德尔在其着述中讲了海洛因问世、上市和作为药品最终没落的故事,他描述了一个令人惊讶的时代。

事实上,海洛因并非最早出自霍夫曼之手,早在1874年,英国药剂师埃尔德 莱特就首度人工合成了海洛因,但并未引起关注。直到霍夫曼再度独立合成,才开始进入人们的视野,此后的很长一段时间,“世界似乎是颠倒的,大家都很狂热”。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=94300, encodeId=50b5943008c, content=太有意思了,魔鬼与天使, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sat Jul 23 15:08:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48023, encodeId=8254480230b, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48024, encodeId=e8a548024ea, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48025, encodeId=6f9e4802564, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48026, encodeId=d1934802638, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48027, encodeId=ecd34802eee, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48028, encodeId=6123480289c, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523493, encodeId=565d152349347, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Wed Nov 19 00:28:00 CST 2014, time=2014-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12545, encodeId=24201254506, content=药物的滥用不是研发者的错。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160403/IMG5700F9EC14BED9452.jpg, createdBy=879d37419, createdName=cjyisheng, createdTime=Mon Nov 17 22:58:00 CST 2014, time=2014-11-17, status=1, ipAttribution=)]
    2016-07-23 午夜星河

    太有意思了,魔鬼与天使

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=94300, encodeId=50b5943008c, content=太有意思了,魔鬼与天使, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sat Jul 23 15:08:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48023, encodeId=8254480230b, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48024, encodeId=e8a548024ea, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48025, encodeId=6f9e4802564, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48026, encodeId=d1934802638, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48027, encodeId=ecd34802eee, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48028, encodeId=6123480289c, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523493, encodeId=565d152349347, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Wed Nov 19 00:28:00 CST 2014, time=2014-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12545, encodeId=24201254506, content=药物的滥用不是研发者的错。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160403/IMG5700F9EC14BED9452.jpg, createdBy=879d37419, createdName=cjyisheng, createdTime=Mon Nov 17 22:58:00 CST 2014, time=2014-11-17, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    值得收藏,学习,谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=94300, encodeId=50b5943008c, content=太有意思了,魔鬼与天使, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sat Jul 23 15:08:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48023, encodeId=8254480230b, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48024, encodeId=e8a548024ea, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48025, encodeId=6f9e4802564, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48026, encodeId=d1934802638, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48027, encodeId=ecd34802eee, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48028, encodeId=6123480289c, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523493, encodeId=565d152349347, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Wed Nov 19 00:28:00 CST 2014, time=2014-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12545, encodeId=24201254506, content=药物的滥用不是研发者的错。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160403/IMG5700F9EC14BED9452.jpg, createdBy=879d37419, createdName=cjyisheng, createdTime=Mon Nov 17 22:58:00 CST 2014, time=2014-11-17, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    值得收藏,学习,谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=94300, encodeId=50b5943008c, content=太有意思了,魔鬼与天使, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sat Jul 23 15:08:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48023, encodeId=8254480230b, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48024, encodeId=e8a548024ea, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48025, encodeId=6f9e4802564, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48026, encodeId=d1934802638, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48027, encodeId=ecd34802eee, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48028, encodeId=6123480289c, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523493, encodeId=565d152349347, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Wed Nov 19 00:28:00 CST 2014, time=2014-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12545, encodeId=24201254506, content=药物的滥用不是研发者的错。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160403/IMG5700F9EC14BED9452.jpg, createdBy=879d37419, createdName=cjyisheng, createdTime=Mon Nov 17 22:58:00 CST 2014, time=2014-11-17, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    值得收藏,学习,谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=94300, encodeId=50b5943008c, content=太有意思了,魔鬼与天使, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sat Jul 23 15:08:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48023, encodeId=8254480230b, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48024, encodeId=e8a548024ea, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48025, encodeId=6f9e4802564, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48026, encodeId=d1934802638, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48027, encodeId=ecd34802eee, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48028, encodeId=6123480289c, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523493, encodeId=565d152349347, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Wed Nov 19 00:28:00 CST 2014, time=2014-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12545, encodeId=24201254506, content=药物的滥用不是研发者的错。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160403/IMG5700F9EC14BED9452.jpg, createdBy=879d37419, createdName=cjyisheng, createdTime=Mon Nov 17 22:58:00 CST 2014, time=2014-11-17, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    值得收藏,学习,谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=94300, encodeId=50b5943008c, content=太有意思了,魔鬼与天使, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sat Jul 23 15:08:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48023, encodeId=8254480230b, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48024, encodeId=e8a548024ea, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48025, encodeId=6f9e4802564, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48026, encodeId=d1934802638, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48027, encodeId=ecd34802eee, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48028, encodeId=6123480289c, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523493, encodeId=565d152349347, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Wed Nov 19 00:28:00 CST 2014, time=2014-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12545, encodeId=24201254506, content=药物的滥用不是研发者的错。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160403/IMG5700F9EC14BED9452.jpg, createdBy=879d37419, createdName=cjyisheng, createdTime=Mon Nov 17 22:58:00 CST 2014, time=2014-11-17, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    值得收藏,学习,谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=94300, encodeId=50b5943008c, content=太有意思了,魔鬼与天使, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sat Jul 23 15:08:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48023, encodeId=8254480230b, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48024, encodeId=e8a548024ea, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48025, encodeId=6f9e4802564, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48026, encodeId=d1934802638, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48027, encodeId=ecd34802eee, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48028, encodeId=6123480289c, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523493, encodeId=565d152349347, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Wed Nov 19 00:28:00 CST 2014, time=2014-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12545, encodeId=24201254506, content=药物的滥用不是研发者的错。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160403/IMG5700F9EC14BED9452.jpg, createdBy=879d37419, createdName=cjyisheng, createdTime=Mon Nov 17 22:58:00 CST 2014, time=2014-11-17, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    值得收藏,学习,谢谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=94300, encodeId=50b5943008c, content=太有意思了,魔鬼与天使, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sat Jul 23 15:08:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48023, encodeId=8254480230b, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48024, encodeId=e8a548024ea, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48025, encodeId=6f9e4802564, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48026, encodeId=d1934802638, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48027, encodeId=ecd34802eee, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48028, encodeId=6123480289c, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523493, encodeId=565d152349347, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Wed Nov 19 00:28:00 CST 2014, time=2014-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12545, encodeId=24201254506, content=药物的滥用不是研发者的错。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160403/IMG5700F9EC14BED9452.jpg, createdBy=879d37419, createdName=cjyisheng, createdTime=Mon Nov 17 22:58:00 CST 2014, time=2014-11-17, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=94300, encodeId=50b5943008c, content=太有意思了,魔鬼与天使, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sat Jul 23 15:08:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48023, encodeId=8254480230b, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48024, encodeId=e8a548024ea, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48025, encodeId=6f9e4802564, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=172, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48026, encodeId=d1934802638, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48027, encodeId=ecd34802eee, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=183, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48028, encodeId=6123480289c, content=值得收藏,学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 14:29:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523493, encodeId=565d152349347, content=<a href='/topic/show?id=510865640d9' target=_blank style='color:#2F92EE;'>#海洛因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65640, encryptionId=510865640d9, topicName=海洛因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=27e211527640, createdName=xuqianhua, createdTime=Wed Nov 19 00:28:00 CST 2014, time=2014-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12545, encodeId=24201254506, content=药物的滥用不是研发者的错。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160403/IMG5700F9EC14BED9452.jpg, createdBy=879d37419, createdName=cjyisheng, createdTime=Mon Nov 17 22:58:00 CST 2014, time=2014-11-17, status=1, ipAttribution=)]
    2014-11-17 cjyisheng

    药物的滥用不是研发者的错。

    0

相关资讯

Ann Oncol:长期服用阿司匹林可降低癌症发病率,整体获益大于风险

一项综述性研究发现,长期服用阿司匹林可降低癌症发病风险。伦敦大学的Jack Cuzick1教授称,虽然每日服用75mg 即可,然而服用阿司匹林潜在副作用(其中包括卒中和内出血)是致命的。 如果每位年龄在50-64岁的英国人服用阿司匹林达十年,每年就可挽救六***免于死亡—四千名男性和两千名女性。据估计,在20年中可避免130,357 名癌症患者死亡,包括9,473名先前经历心脏问题的心脏疾患者。由于

J Am Med Inform Assoc:美国将采用3千万患者大数据研究阿司匹林疗效

        一项大数据研究将搞清不同剂量的阿司匹林对于心脏病有何种疗效。         图片来源:Richard Levine/Alamy 医疗卫生领域迄今最大的一项大数据试验终于设定了第一个研究目

Cancer Res:NSAIDs降低乳腺癌肥胖患者癌症复发风险

近日,一项新研究确定,接受激素治疗作为治疗方案一部分的绝经后体重超重或肥胖的乳腺癌患者,使用非甾体抗炎药(NSAIDs)如阿司匹林或布洛芬,乳腺癌复发率显著降低和癌复发时间大大延迟。这项研究结果发表在8月14日的Cancer Research杂志上,新研究提示了一种减少超重和肥胖绝经后妇女(这些女性复发的相对风险较高)乳腺癌复发率的新可能性。对人体临床研究和细胞培养实验研究进行回顾性分析,研究人员

丁亚辉 :阿司匹林该到底该怎么用?

阿司匹林是非常常用的抗血栓药物,对于冠心病和脑卒中患者更是必不可少的基本药物。但很多人都认为阿司匹林对胃有损伤,应该餐后服用,但实际情况并非如此。   目前国内销售的阿司匹林基本都是阿司匹林肠溶片。肠溶片的设计目的就是避免阿司匹林在胃中被吸收,肠衣在胃酸的环境下是不会分解的,而在肠道碱性的环境下阿司匹林才被释放出来起作用。这种设计大大减少了阿司匹林对胃的损伤,也改变了阿司匹林的服

PNAS:非甾体抗炎药如何预防大肠癌

来自美国匹兹堡大学癌症研究所(UPCI)的研究人员在一项新研究中证实,阿司匹林和其他的非甾体抗炎药物(NSAIDs)能够通过在携带某一功能异常的突变基因的肠干细胞中诱导细胞自杀信号途径,来预防大肠癌形成。他们的研究结果发布在《美国国家科学院院刊》(PNAS)上。 高级研究员、匹兹堡医学院药理学与化学生物学系及匹兹堡大学癌症研究所副教授张林(Lin Zhang)博士说,科学家们很

PANS:阿司匹林抗炎的第二条途径

现已高度普及的非甾体抗炎药,例如阿司匹林、萘普生、布洛芬,都是通过抑制或消灭环氧酶来发挥效用的,而环氧酶是前列腺素产生过程中的关键催化剂,与一系列疾病相关,例如头痛、关节炎、痛经、脓毒症。发表于本周PNAS在线期刊的一篇最新研究报到中,来自加州大学、圣地亚哥医学院的研究人员表示,阿司匹林还有另外一个效用。它不仅能消灭环氧酶,还能够预防导致炎症和疼痛的前列腺素产生。同时这也提示我们环氧酶会形成另一种

Baidu
map
Baidu
map
Baidu
map